EirGenix is a global contract development and manufacturing organization CDMO providing high quality and cost-effectiveness service in support of its clients in the development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing. EirGenix quality system follows global quality guidelines and has passed US FDA, Japan PDMA and Taiwan local TFDA GMP inspection for commercial supplies. EirGenix is also a leader in the development of HER2 related biosimilars. EirGenix has formed a licensing agreement with Sandoz to ex-China globally market of its self-developed trastuzumab biosimilar product. EirGenix provides a one-stop shop solution to its clients in the development and manufacturing of biologics around the world.